Presage Biosciences is an oncology company that is pioneering an entirely novel approach to evaluating drug responses in clinical trials.
Presage’s patented CIVO® technology delivers microdoses of multiple drugs to different regions of a tumor – while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring human tumor has the potential to provide a more detailed understanding of tumor biology, directly embodying a patient’s own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to use this understanding to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.
Presage collaborates with biopharmaceutical companies to discover new drug combinations and assess novel agents in the most important model of cancer — the human patient.